Literature DB >> 29399392

Pro-inflammatory allogeneic DCs promote activation of bystander immune cells and thereby license antigen-specific T-cell responses.

Grammatiki Fotaki1, Chuan Jin1, Mohanraj Ramachandran1, Iliana Kyriaki Kerzeli1, Alex Karlsson-Parra1,2, Di Yu1, Magnus Essand1.   

Abstract

Accumulating evidence support an important role for endogenous bystander dendritic cells (DCs) in the efficiency of autologous patient-derived DC-vaccines, as bystander DCs take up material from vaccine-DCs, migrate to draining lymph node and initiate antitumor T-cell responses. We examined the possibility of using allogeneic DCs as vaccine-DCs to activate bystander immune cells and promote antigen-specific T-cell responses. We demonstrate that human DCs matured with polyI:C, R848 and IFN-γ (denoted COMBIG) in combination with an infection-enhanced adenovirus vector (denoted Ad5M) exhibit a pro-inflammatory state. COMBIG/Ad5M-matured allogeneic DCs (alloDCs) efficiently activated T-cells and NK-cells in allogeneic co-culture experiments. The secretion of immunostimulatory factors during the co-culture promoted the maturation of bystander-DCs, which efficiently cross-presented a model-antigen to activate antigen-specific CD8+ T-cells in vitro. We propose that alloDCs, in combination with Ad5M as loading vehicle, may be a cost-effective and logistically simplified DC vaccination strategy to induce anti-tumor immune responses in cancer patients.

Entities:  

Keywords:  Allogeneic dendritic cells; cell activation; cell-based immunotherapy; innate immune cells

Year:  2017        PMID: 29399392      PMCID: PMC5790348          DOI: 10.1080/2162402X.2017.1395126

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  25 in total

1.  Direct allorecognition promotes activation of bystander dendritic cells and licenses them for Th1 priming: a functional link between direct and indirect allosensitization.

Authors:  A C Wallgren; B Andersson; A Bäcker; A Karlsson-Parra
Journal:  Scand J Immunol       Date:  2005-09       Impact factor: 3.487

Review 2.  Targeted antigen delivery and activation of dendritic cells in vivo: steps towards cost effective vaccines.

Authors:  Paul J Tacken; Carl G Figdor
Journal:  Semin Immunol       Date:  2011-01-26       Impact factor: 11.130

3.  A novel flow cytometric method to assess inflammasome formation.

Authors:  David P Sester; Sara J Thygesen; Vitaliya Sagulenko; Parimala R Vajjhala; Jasmyn A Cridland; Nazarii Vitak; Kaiwen W Chen; Geoffrey W Osborne; Kate Schroder; Katryn J Stacey
Journal:  J Immunol       Date:  2014-11-17       Impact factor: 5.422

Review 4.  Clinical use of dendritic cells for cancer therapy.

Authors:  Sébastien Anguille; Evelien L Smits; Eva Lion; Viggo F van Tendeloo; Zwi N Berneman
Journal:  Lancet Oncol       Date:  2014-06       Impact factor: 41.316

5.  Collapse of the tumor stroma is triggered by IL-12 induction of Fas.

Authors:  Sid P Kerkar; Anthony J Leonardi; Nicolas van Panhuys; Ling Zhang; Zhiya Yu; Joseph G Crompton; Jenny H Pan; Douglas C Palmer; Richard A Morgan; Steven A Rosenberg; Nicholas P Restifo
Journal:  Mol Ther       Date:  2013-04-09       Impact factor: 11.454

6.  Interleukin-15 Dendritic Cells Harness NK Cell Cytotoxic Effector Function in a Contact- and IL-15-Dependent Manner.

Authors:  Sébastien Anguille; Heleen H Van Acker; Johan Van den Bergh; Yannick Willemen; Herman Goossens; Viggo F Van Tendeloo; Evelien L Smits; Zwi N Berneman; Eva Lion
Journal:  PLoS One       Date:  2015-05-07       Impact factor: 3.240

7.  Avidity characterization of genetically engineered T-cells with novel and established approaches.

Authors:  Victoria Hillerdal; Vanessa F Boura; Hanna Björkelund; Karl Andersson; Magnus Essand
Journal:  BMC Immunol       Date:  2016-07-13       Impact factor: 3.615

8.  Enhanced stimulation of human tumor-specific T cells by dendritic cells matured in the presence of interferon-γ and multiple toll-like receptor agonists.

Authors:  Tanja Lövgren; Dhifaf Sarhan; Iva Truxová; Bhavesh Choudhary; Roeltje Maas; Jeroen Melief; Maria Nyström; Ulrika Edbäck; Renee Vermeij; Gina Scurti; Michael Nishimura; Giuseppe Masucci; Alex Karlsson-Parra; Andreas Lundqvist; Lars Adamson; Rolf Kiessling
Journal:  Cancer Immunol Immunother       Date:  2017-06-10       Impact factor: 6.968

9.  Adenovirus serotype 5 vectors with Tat-PTD modified hexon and serotype 35 fiber show greatly enhanced transduction capacity of primary cell cultures.

Authors:  Di Yu; Chuan Jin; Mohanraj Ramachandran; Jing Xu; Berith Nilsson; Olle Korsgren; Katarina Le Blanc; Lene Uhrbom; Karin Forsberg-Nilsson; Bengt Westermark; Rachel Adamson; Norman Maitland; Xiaolong Fan; Magnus Essand
Journal:  PLoS One       Date:  2013-01-25       Impact factor: 3.240

Review 10.  Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines.

Authors:  Lien Vandenberk; Jochen Belmans; Matthias Van Woensel; Matteo Riva; Stefaan W Van Gool
Journal:  Front Immunol       Date:  2016-01-14       Impact factor: 7.561

View more
  14 in total

Review 1.  Trial watch: dendritic cell vaccination for cancer immunotherapy.

Authors:  Jenny Sprooten; Jolien Ceusters; An Coosemans; Patrizia Agostinis; Steven De Vleeschouwer; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi; Abhishek D Garg
Journal:  Oncoimmunology       Date:  2019-07-18       Impact factor: 8.110

2.  Phase 1 Trial With the Cell-Based Immune Primer Ilixadencel, Alone, and Combined With Sorafenib, in Advanced Hepatocellular Carcinoma.

Authors:  Magnus Rizell; Malin Sternby Eilard; Mats Andersson; Bengt Andersson; Alex Karlsson-Parra; Peter Suenaert
Journal:  Front Oncol       Date:  2019-01-21       Impact factor: 6.244

Review 3.  Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology.

Authors:  Isaure Vanmeerbeek; Jenny Sprooten; Dirk De Ruysscher; Sabine Tejpar; Peter Vandenberghe; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi; Abhishek D Garg
Journal:  Oncoimmunology       Date:  2020-01-09       Impact factor: 8.110

Review 4.  Interleukin-1 as Innate Mediator of T Cell Immunity.

Authors:  Bram Van Den Eeckhout; Jan Tavernier; Sarah Gerlo
Journal:  Front Immunol       Date:  2021-01-27       Impact factor: 7.561

5.  Compromised functionality of monocyte-derived dendritic cells in multiple myeloma patients may limit their use in cancer immunotherapy.

Authors:  Prajakta Shinde; Sophia Fernandes; Sameer Melinkeri; Vaijayanti Kale; Lalita Limaye
Journal:  Sci Rep       Date:  2018-04-09       Impact factor: 4.379

6.  Ilixadencel - an Allogeneic Cell-Based Anticancer Immune Primer for Intratumoral Administration.

Authors:  Alex Karlsson-Parra; Juliana Kovacka; Emilia Heimann; Margareth Jorvid; Sijme Zeilemaker; Sharon Longhurst; Peter Suenaert
Journal:  Pharm Res       Date:  2018-06-14       Impact factor: 4.200

Review 7.  Dendritic Cells (DCs) as "Fire Accelerants" of Hantaviral Pathogenesis.

Authors:  Günther Schönrich; Martin J Raftery
Journal:  Viruses       Date:  2019-09-13       Impact factor: 5.048

Review 8.  Exosomal miRNAs in tumor microenvironment.

Authors:  Shiming Tan; Longzheng Xia; Pin Yi; Yaqian Han; Lu Tang; Qing Pan; Yutong Tian; Shan Rao; Linda Oyang; Jiaxin Liang; Jinguan Lin; Min Su; Yingrui Shi; Deliang Cao; Yujuan Zhou; Qianjin Liao
Journal:  J Exp Clin Cancer Res       Date:  2020-04-16

9.  Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer.

Authors:  Jing Ma; Mohanraj Ramachandran; Chuan Jin; Clara Quijano-Rubio; Miika Martikainen; Di Yu; Magnus Essand
Journal:  Cell Death Dis       Date:  2020-01-22       Impact factor: 8.469

10.  Allogeneic dendritic cells induce potent antitumor immunity by activating KLRG1+CD8 T cells.

Authors:  Chao Wang; Zhengyuan Li; Zhongli Zhu; Yijie Chai; Yiqing Wu; Zhenglong Yuan; Zhijie Chang; Zhao Wang; Minghui Zhang
Journal:  Sci Rep       Date:  2019-10-29       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.